<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002759</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02242</org_study_id>
    <secondary_id>UCCRC-8033</secondary_id>
    <secondary_id>NCI-T95-0100H</secondary_id>
    <secondary_id>CDR0000064707</secondary_id>
    <nct_id>NCT00002759</nct_id>
  </id_info>
  <brief_title>Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma</brief_title>
  <official_title>A PHASE I STUDY OF IRINOTECAN (CPT-11) WITH PHARMACOKINETIC MODULATION BY CYCLOSPORINE A AND PHENOBARBITAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of irinotecan plus cyclosporine and phenobarbital in&#xD;
      treating patients who have solid tumors or lymphoma that is refractory to standard therapy.&#xD;
      Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop&#xD;
      growing or die. Cyclosporine and phenobarbital may enhance the effectiveness of irinotecan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of irinotecan (CPT-11) when infused weekly with&#xD;
      cyclosporine (CYSP) in patients with solid tumors or lymphoma refractory to standard therapy.&#xD;
&#xD;
      II. Determine whether CYSP modulates the pharmacokinetics and pharmacodynamics of CPT-11 and&#xD;
      its active metabolite, SN-38.&#xD;
&#xD;
      III. Determine whether phenobarbital modulates the pharmacokinetics and pharmacodynamics of&#xD;
      CPT-11 and SN-38.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of irinotecan. Patients are stratified according to&#xD;
      gender.&#xD;
&#xD;
      Part I: Patients receive cyclosporine IV over 6 hours and irinotecan IV over 90 minutes&#xD;
      weekly for 4 weeks. Courses repeat every 6 weeks in the absence of unacceptable toxicity or&#xD;
      disease progression. Cohorts of 3-12 patients receive escalating doses of irinotecan until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which at&#xD;
      least one third of patients experience dose limiting toxicity (DLT).&#xD;
&#xD;
      Part IIA: If the DLT is diarrhea in part I, then part IIA is opened. Patients receive oral&#xD;
      phenobarbital, cyclosporine as in part I, and irinotecan at the MTD from part I. Dose&#xD;
      escalation occurs as in part I to determine a new MTD. If the DLT continues to be diarrhea,&#xD;
      the study is closed. Part IIB: If the DLT is neutropenia in part I, then part IIB is opened.&#xD;
      Patients receive cyclosporine as in part I and escalating doses of irinotecan to determine a&#xD;
      new MTD.&#xD;
&#xD;
      Part III: If the DLT is neutropenia in part IIA or any DLT in part IIB, patients receive&#xD;
      phenobarbital, cyclosporine, and irinotecan at the MTD determined as in part IIA or part IIB.&#xD;
      Dose escalation continues until a new MTD is determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1996</start_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Drug/Agent Toxicity by Tissue/Organ</condition>
  <condition>Lymphoma</condition>
  <condition>Neutropenia</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phenobarbital</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Malignant solid tumor or lymphoma refractory to standard therapy or for which no&#xD;
             therapy of proven benefit exists&#xD;
&#xD;
          -  No leukemia&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance status: Karnofsky 70-100%&#xD;
&#xD;
          -  Life expectancy: At least 3 months&#xD;
&#xD;
          -  WBC at least 3,500/mm3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT less than twice normal (unless due to disease)&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No history of congestive heart failure requiring medical therapy&#xD;
&#xD;
          -  No clinically significant or life threatening cardiac arrhythmia&#xD;
&#xD;
          -  No history of significant pulmonary disease or lymphangitic lung disease&#xD;
&#xD;
          -  No hypersensitivity to cyclosporine or cremophore&#xD;
&#xD;
          -  No history of manifest or latent porphyria or hypersensitivity to barbiturates (for&#xD;
             parts of study using phenobarbital)&#xD;
&#xD;
          -  No history of inflammatory bowel disease requiring therapy&#xD;
&#xD;
          -  No chronic diarrhea syndrome or paralytic ileus&#xD;
&#xD;
          -  No medical or psychiatric condition that precludes informed consent&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Effective contraception required of fertile women&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  At least 2 weeks since prior colony stimulating factors&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (at least 6 weeks since nitrosoureas or&#xD;
             mitomycin)&#xD;
&#xD;
          -  No prior bleomycin or irinotecan&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to greater than 25% of bone marrow&#xD;
&#xD;
          -  Minimum time interval between prior therapy and eligibility shortened by 2 weeks when&#xD;
             phenobarbital is administered&#xD;
&#xD;
          -  Concurrent use of medications that affect the central nervous or cardiovascular&#xD;
             systems (e.g., anticonvulsants, calcium channel blockers, oral contraceptives) must be&#xD;
             approved by the Principal Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J. Ratain, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2004</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <keyword>neutropenia</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Phenobarbital</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

